Protocol Ledger

NCT07136012 · Phase III · RECRUITING

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Interventional Phase III clinical trial protocol NCT07136012 sponsored by Amgen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-22 Enrollment: 11,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07136012
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)11,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07136012
Protocol FieldVerified Registry Value
NCT IdentifierNCT07136012
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment11,000 participants (ESTIMATED)
Registered Start Date2025-08-22
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI